Please use this identifier to cite or link to this item:
|Title:||Two year clinical outcomes after sirolimus-eluting stent implantation for the treatment of coronary artery disease||Authors:||Adam, Jamila Khatoon
Dyer, Robby B.
|Keywords:||Coronary artery disease;Serolimus-eluting stents;Cypher select||Issue Date:||2012||Publisher:||Medical Technology SA||Source:||Jamila Khatoon Adam, Robby Dyer, Ashika Harrypaul, Wafaa Rmaih. "Two year clinical outcomes after sirolimus-eluting stent implantation for the treatment of coronary artery disease". Medical Technology SA. Vol. 26, no. 1 (2012): 18-21||Abstract:||Background Coronary artery stents are known to reduce rates of restenosis after coronary stenting, but it is uncertain how long this benefit is maintained. Clinical data has raised concerns that drug-eluting stents are associated with increased rates of late stent thrombosis, death or myocardial infarction. Objectives To evaluate the safety and reliability of sirolimus-eluting stents in real-world practice out to two years. Methods From January 2008 to June 2008, 30 patients were enrolled in the study after implantation of one or more sirolimus-eluting stents. We evaluated clinical follow-up information for up to two years after the implantation of Cypher® Select stents in 30 patients with 35 lesions. Results Mean patient age was 62.33 +/- 10.99 years, 7 percent were diabetic and 30 percent presented with acute myocardial infarctions. The procedure’s success rate was 100 percent for the sirolimus-eluting stent implantation, and follow-up rates were 100 percent. Mean total stent length was 22.32 +/- 6.63 mm, with 13 percent receiving more than one stent. Two year freedom from mortality, myocardial infarction, target vessel revascularization and stent thrombosis was 100 percent. Dual antiplatelet therapy was taken by 100 percent at 1 month, 53 percent at 6 months, 40 percent at 1 year and 0 percent of patients at 2 years. The rate of survival free of myocardial infarction, bypass surgery and repeated angioplasty for stented lesions was 100% at two years. Conclusions Treatment of lesions with sirolimus-eluting stents is associated with a sustained clinical benefit two years after device implantation.||URI:||http://hdl.handle.net/10321/789||ISSN:||1011 5528||Rights:||This work is licensed under a Creative Commons Attribution License.|
|Appears in Collections:||Research Publications (Health Sciences)|
Show full item record
Files in This Item:
|Adam_Harrypaul_Rmaih_2012.pdf||1.13 MB||Adobe PDF|
Page view(s) 50848
checked on Feb 18, 2019
checked on Feb 18, 2019
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.